Dr. Bosse Discusses Bone-Targeted Agents in RCC

Dominick Bosse, MD
Published: Tuesday, Mar 13, 2018



Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).

Bone-targeted agents are used in RCC but are a part of supportive care, says Bosse. It is controversial because part of the data come from a small subset of heterogeneous larger trials that were carried on before the era of targeted therapy. Now that there are so many options for the treatment of patients with RCC, it is harder to determine which regimen is the best choice, adds Bosse.

Bone-targeted agents are still used but need to be used carefully, particularly when combined with VEGF-targeted agents, as they can increase side effects. It is reserved for patients with bone pain or a higher burden of bone disease.
 


Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).

Bone-targeted agents are used in RCC but are a part of supportive care, says Bosse. It is controversial because part of the data come from a small subset of heterogeneous larger trials that were carried on before the era of targeted therapy. Now that there are so many options for the treatment of patients with RCC, it is harder to determine which regimen is the best choice, adds Bosse.

Bone-targeted agents are still used but need to be used carefully, particularly when combined with VEGF-targeted agents, as they can increase side effects. It is reserved for patients with bone pain or a higher burden of bone disease.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x